Table 5 Results of cost-effectiveness analysis (BRL/ months of life gained)
Strategy | Cost (R$) | Incremental cost (R$) | Effectiveness (MLG) | Incremental effectiveness (MLG) | ICER (BRL/MLG) |
|---|---|---|---|---|---|
XELOX | 41,396.84 | 97.07 | |||
XELOX + bevacizumab | 89,230.41 | 47,833.57 | 99.32 | 2.25 | 21,231.43 |